Skip to main content
Top
Published in:

Open Access 04-06-2024 | Breast Cancer | Original Research

Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis

Authors: Mirosława Püsküllüoğlu, Małgorzata Pieniążek, Agnieszka Rudzińska, Agnieszka Pietruszka, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marek Ziobro

Published in: Oncology and Therapy | Issue 3/2024

Login to get access

Abstract

Introduction

Hepatic visceral crisis (VC), characterized by a rapid total bilirubin increase with disease progression, poses a life-threatening risk in advanced breast cancer (ABC). International consensus guidelines define VC and touch on impending VC (IVC). Limited data exist on systemic treatments for hepatic VC/IVC. This study explores the safety and efficacy of cisplatin monotherapy in patients with Human Epidermal Growth Factor Receptor 2- negative breast cancer (BC) and hepatic IVC/VC.

Methods

In this retrospective single-center cohort study data of patients treated with cisplatin monotherapy (60–80 mg/m2, every 3–4 weeks) between 2016 and 2023 at a reference Cancer Centre in Southern Poland were analyzed.

Results

33 female patients (24/33 hormonal-positive) with the mean age 53.84 years were included. Participants progressed on median 2 prior palliative systemic treatment lines. In 10/23 patients hepatic VC and in 23/33 IVC (rapid, symptomatic liver progression; extensive liver involvement; alanine or aspartate aminotransferase > 2 × normal limit; significant increases in lactate dehydrogenase, alkaline phosphatase, or gamma-glutamyl transferase) were identified. Median progression-free survival was 1.87 months and median overall survival 2.67 months. 33% of the patients presented stable disease or partial response. Eight patients experienced adverse events grade ≥ 3: in five the dose of cisplatin was reduced; two stopped the treatment.

Conclusion

Due to the hepatotoxicity of BC-active drugs, specific recommendations for systemic treatment are scarce. Our study explored cisplatin's potential use, finding it to be a viable option in patients with performance status 0 or 1 experiencing hepatic IVC/VC, irrespective of liver function parameters and other factors.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis
Authors
Mirosława Püsküllüoğlu
Małgorzata Pieniążek
Agnieszka Rudzińska
Agnieszka Pietruszka
Renata Pacholczak-Madej
Aleksandra Grela-Wojewoda
Marek Ziobro
Publication date
04-06-2024
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 3/2024
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-024-00280-9

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ASCO 2025 Annual Meeting

Keep up to date with the latest in oncology research with our ASCO 2025 hub page, featuring official videos, breaking news, and more.

Read more

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more